Industry-leading sensitivity and specificity shown across all classes of genomic alterations relevant to non-small cell lung cancer

Inivata has announced the publication of the analytical validation of its InVisionFirst-Lung targeted advanced sequencing test. The results were published in PLoS ONE and build on previous development work on the InVision platform also recently published in PLoS ONE.

The InVisionFirst-Lung test is intended to aid clinicians in treatment decisions for non-small cell lung cancer (NSCLC), using targeted advanced sequencing technology to detect cancer genomic alterations in selected genes from circulating tumor DNA (ctDNA) isolated from plasma samples.

The test provides comprehensive genomic profiling from circulating tumor DNA, to identity actionable genomic alterations in genes commonly mutated in NSCLC and other cancer types. The assay has been developed to detect point mutations, indels, amplifications and gene fusions that commonly occur in NSCLC.

Given the low concentration of ctDNA relative to total cell-free DNA in circulation, detection of somatic mutations from ctDNA requires very high sensitivity to deliver clinical benefits to the broadest patient population. InVisionFirst-Lung was shown to demonstrate industry-leading sensitivity and specificity across all classes of genomic alterations relevant to NSCLC.

Michael Stocum, Chief Executive Officer of Inivata, said: “This ongoing rigorous validation showed the InVisionFirst-Lung assay to be highly sensitive, specific and robust, achieving the analytical requirements for the delivery of valuable clinical information to aid the treatment of lung cancer. We believe we have demonstrated levels of sensitivity and specificity beyond those published for other liquid biopsy platforms and which could bring significant benefits for clinical applications.

Read more here